The global tangential flow filtration market is experiencing growth and is projected to reach USD 3,667.2 million by 2030. The development in the biopharmaceutical industry, mainly the progress of biologics and biosimilars making; augmented expenditure in RD by market participants; and benefits of tangential flow filtration in comparison to normal flow filtration is the major reason propelling the industry development.
The membrane filters category grips the maximum revenue share, of approximately 40%, in the tangential flow filtration industry, as these are extensively utilized in biologics making and lab settings. Among the membrane filters, the polyethersulfone category is responsible or above half of the revenue share, and it is estimated to experience substantial development during the projection period. This can be credited to the extensive application of polyethersulfone membrane filters in the making of vaccines and extracting proteins.
However, the requirement for single-use tangential flow filtration systems is attaining traction during the projection period, advancing at a CAGR of above 13%. This is because it aids in the decrease of labor expanse by above 50% and water utilization and buffer by above 70%. Furthermore, it can surge efficiency by above 40%. Additionally, end users are choosing single-use TFF systems over reusable TFF systems, as the former is around 30% more inexpensive compared to the latter.
Download free sample copy of this report: https://www.psmarketresearch.com/market-analysis/tangential-flow-filtration-market/report-sample
Microfiltration and Ultrafiltration are the 2 main technologies accepted in tangential flow filtration. Ultrafiltration technology has been responsible for above 65% of the industry share in recent years. The sales of ultrafiltration membranes are gaining traction, as they can discrete biomolecules with small pore size, i.e., 0.01–0.1 μm, supporting in decreasing the making expanse of biopharmaceutical items.
In recent years, North America dominated the tangential flow filtration market with a revenue share of 35%, and the region is projected to stay dominant in the future as well. This is credited to the rise in acceptance of progressive tech by biomanufacturing businesses, the existence of key biomanufacturing amenities, and the surge in the count of new medication development projects, in the region.
In North America, the U.S. industry grips a larger share; whereas, the Canadian industry is projected to experience substantial development, of above 13.5% CAGR, during the projection period. In recent years, on average, 12 new biologics medications were permitted per annum in the U.S. Also, national governments in the continent have been growing backing in the biotechnology industry to fuel RD, along with educating people in this field. For example, in FY 2022, the U.S. government planned a TO fund of USD 382.26 million for biotechnology, compared to the recent funding of USD 324.61 million in FY 2020.
